CEL SCI CORP 8-K

What Happened
CEL‑SCI Corp (ticker: CVM) filed an 8‑K on May 14, 2026 reporting a strategic partnership, distribution and revenue‑sharing agreement with Amarox. The press release announcing the deal was issued May 11, 2026. The agreement covers regulatory affairs, marketing and potential commercialization of Multikine (Leukocyte Interleukin, Injection) for the treatment of head and neck cancer in Saudi Arabia, with an optional extension to the other Gulf Cooperation Council (GCC) countries.

Key Details

• Parties: CEL‑SCI Corp and Amarox.
• Product: Multikine (Leukocyte Interleukin, Injection) for head and neck cancer.
• Scope: Regulatory affairs, marketing and potential commercialization in Saudi Arabia; optional extension to GCC (Bahrain, Kuwait, Oman, Qatar, UAE).
• Timing & filings: Press release dated May 11, 2026; Form 8‑K filed May 14, 2026; the written agreement and press release were filed as exhibits.
• Financial terms: The 8‑K does not disclose specific financial terms or dollar amounts.

Why It Matters
This agreement creates a formal pathway for CEL‑SCI to pursue market access for Multikine in Saudi Arabia and potentially across the GCC through a local partner focused on regulatory and commercial execution. For investors, the partnership may accelerate regional development and future revenue opportunities if regulatory approvals and commercialization are successful — but the 8‑K includes no financial details, and future outcomes depend on regulatory review, commercial execution, and any subsequent disclosures.